Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

Steven A. Rosenberg, Michael T. Lotze, Linda Muul et al. · New England Journal of Medicine · 1987 · 2.8K citations

Lymphoid Neoplasia, Advanced Cancer, Cancer Immunosurveillance +15

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Elizabeth A. Grimm, A Mazumder, H Z Zhang et al. · The Journal of Experimental Medicine · 1982 · 2.2K citations · Full text

Immunology, Immunologic Mechanism, Immune System +16

Randomized Comparisons of Radiotherapy and Nitrosoureas for the Treatment of Malignant Glioma after Surgery

Michael Walker, Sylvan B. Green, David P. Byar et al. · New England Journal of Medicine · 1980 · 1.6K citations

Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

Michael T. Lotze, Elizabeth A. Grimm, Amitabha Mazumder et al. · PubMed · 1981 · 523 citations

Lymphoid Neoplasia, Selective Lysis, Cancer Immunosurveillance +15

Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

Martin A. Cheever, Philip D. Greenberg, A Fefer et al. · The Journal of Experimental Medicine · 1982 · 268 citations · Full text

Purified Interleukin 2, Cell Therapy, Exogenous Il-2 +19